Project Grant HT94252510122
Award Date
5/1/25
Completion Date
4/30/28
Dollars Obligated
$2.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, Massachusetts. The grant funds a research project to dissect the molecular associations of response to neoadjuvant antiandrogen therapies in high-risk localized prostate cancer. This 4-year research project, running from August 2024 through August 2028,...
Under the $534,000.00 Project Grant awarded by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420), the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) will conduct research to define the role of the androgen receptor in BRCA1/2-deficient prostate cancer. This translational research aims to improve understanding of disease dependencies and develop new treatment approaches for this challenging cancer type. DFCI, a non-profit...
The U.S. Department of Defense's Defense Health Agency has awarded a 4-year, $4,991,950 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development program (CFDA 12.420). The grant will fund DFCI's investigation of a multi-cancer early detection test in a high-risk military population. This research aims to improve health outcomes for military service members, veterans, and the broader public by advancing the development of innovative...
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As...
The Dana-Farber Cancer Institute, Inc. (DFCI) was awarded a $1,574,670 Project Grant from the Defense Health Agency to support the "TUMOR IMMUNOTHERAPY BY GENE-CIRCUIT ENGINEERED RESPONSE (TIGER) GOT NEUROENDOCRINE PROSTATE CANCER" research effort. The grant was awarded on March 15, 2023 under the Military Medical Research and Development program (CFDA 12.420), with work to be completed by March 14, 2026 in Boston, MA.
The Military Medical Research and Development program aims to...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer...
The Department of the Army Medical Command awarded a $945,271 project grant to Dana-Farber Cancer Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420). The three-year award beginning July 1, 2021 will fund research to functionally characterize the noncoding genome of metastatic prostate cancer and identify therapeutic vulnerabilities. Dana-Farber will work with Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis to construct a...
This $1,695,959 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the Dana-Farber Cancer Institute, Inc. (Dfci) to explore the regulatory landscape of pediatric versus adult germ cell tumors. The goal is to gain new therapeutic insights by examining these tumor types within a developmental framework. The 3-year award period runs from September 1, 2023 through August 31, 2026 and will fund basic,...